Literature DB >> 24313956

Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume.

Titus F M Wijnands1, Myrte K Neijenhuis, Wietske Kievit, Frederik Nevens, Marie C Hogan, Vicente E Torres, Tom J G Gevers, Joost P H Drenth.   

Abstract

BACKGROUND & AIMS: Polycystic liver disease (PLD) follows a progressive course ultimately leading to severe hepatomegaly and mechanical complaints in a subset of patients. It is still unknown to what extent this compromises health-related quality of life (HRQL). Our aim was to determine HRQL in PLD patients and investigate its association with concurrent abdominal symptoms and liver volume.
METHODS: Pooled data of 92 severe PLD patients from two randomized clinical trials were used for our cross-sectional analysis. HRQL was assessed using the generic short-form health survey (SF-36) resulting in eight scale scores and the summarizing physical (PCS) and mental component score (MCS). Subsequently, these were compared with the general population. Abdominal symptoms were measured with a standardized, 7-point scale questionnaire in 54 patients. We dichotomized symptoms for absence or presence and compared them with the component scores. Finally, a possible correlation between liver volume and HRQL was explored.
RESULTS: Demographics showed severe polycystic livers (mean 4906 ± 2315 ml). PCS was significantly lower compared with the general population (P < 0.001), in contrast with a similar MCS (P = 0.82). PLD patients had statistically significant (P < 0.05) diminished physical functioning, role physical, general health, vitality and social functioning scores. Upper- and lower abdominal pain and dyspnoea were significantly associated with a reduced PCS (P < 0.01). No correlation was found between liver volume and HRQL.
CONCLUSION: Polycystic liver disease patients had significantly lower HRQL in the physical dimension compared with the general population. Abdominal pain and dyspnoea had a significant impact on this physical dimension of HRQL.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  health-related quality of life; liver volume; polycystic liver disease; symptoms

Mesh:

Year:  2014        PMID: 24313956     DOI: 10.1111/liv.12430

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  19 in total

1.  Incysting transformation.

Authors:  Raffaele Borriello; Maria Grazia Massaro; Andrea Contegiacomo; Rossella Cianci; Giovanni Gambassi
Journal:  Intern Emerg Med       Date:  2021-02-16       Impact factor: 3.397

2.  Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.

Authors:  Tom J G Gevers; Frederik Nevens; Vicente E Torres; Marie C Hogan; Joost P H Drenth
Journal:  Liver Int       Date:  2015-11-09       Impact factor: 5.828

3.  Liver involvement in early autosomal-dominant polycystic kidney disease.

Authors:  Marie C Hogan; Kaleab Abebe; Vicente E Torres; Arlene B Chapman; Kyongtae T Bae; Cheng Tao; Hongliang Sun; Ronald D Perrone; Theodore I Steinman; William Braun; Franz T Winklhofer; Dana C Miskulin; Frederic Rahbari-Oskoui; Godela Brosnahan; Amirali Masoumi; Irina O Karpov; Susan Spillane; Michael Flessner; Charity G Moore; Robert W Schrier
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-09       Impact factor: 11.382

4.  Polycystic liver: automatic segmentation using deep learning on CT is faster and as accurate compared to manual segmentation.

Authors:  Bénédicte Cayot; Laurent Milot; Olivier Nempont; Anna S Vlachomitrou; Carole Langlois-Jacques; Jérôme Dumortier; Olivier Boillot; Karine Arnaud; Thijs R M Barten; Joost P H Drenth; Pierre-Jean Valette
Journal:  Eur Radiol       Date:  2022-02-10       Impact factor: 5.315

5.  Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.

Authors:  Myrte K Neijenhuis; Tom J G Gevers; Marie C Hogan; Patrick S Kamath; Titus F M Wijnands; Ralf C P M van den Ouweland; Marie E Edwards; Jeff A Sloan; Wietske Kievit; Joost P H Drenth
Journal:  Hepatology       Date:  2016-04-15       Impact factor: 17.425

6.  Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.

Authors:  James H Tabibian; Andrea Gossard; Mounif El-Youssef; John E Eaton; Jan Petz; Roberta Jorgensen; Felicity B Enders; Anilga Tabibian; Keith D Lindor
Journal:  Am J Ther       Date:  2017 Jan/Feb       Impact factor: 2.688

7.  Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial.

Authors:  Titus F M Wijnands; Tom J G Gevers; Leo J Schultze Kool; Joost P H Drenth
Journal:  Trials       Date:  2015-03-07       Impact factor: 2.279

8.  Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.

Authors:  Marten A Lantinga; Hedwig M A D'Agnolo; Niek F Casteleijn; Johan W de Fijter; Esther Meijer; Annemarie L Messchendorp; Dorien J M Peters; Mahdi Salih; Edwin M Spithoven; Darius Soonawala; Folkert W Visser; Jack F M Wetzels; Robert Zietse; Joost P H Drenth; Ron T Gansevoort
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

Review 9.  Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management.

Authors:  Wybrich R Cnossen; Joost P H Drenth
Journal:  Orphanet J Rare Dis       Date:  2014-05-01       Impact factor: 4.123

10.  Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Hyunsuk Kim; Hayne Cho Park; Hyunjin Ryu; Kiwon Kim; Hyo Sang Kim; Kook-Hwan Oh; Su Jong Yu; Jin Wook Chung; Jeong Yeon Cho; Seung Hyup Kim; Hae Il Cheong; Kyubeck Lee; Jong Hoon Park; York Pei; Young-Hwan Hwang; Curie Ahn
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.